Recent News

Posted by Burton on March 15th, 2012 in Headlines  ⟩  0 comments
 

ST. LOUIS , MO  Lee Biosolutions Inc, an international manufacturer, producer and supplier of high purity finished proteins and antigens announces  increased production of  beta 2 MICROGLOBULIN .   The St. Louis-based  healthcare- biotechnology firm has  developed a unique  proprietary process to effectively and efficiently purify  B2M in bulk.  As a result, Lee is now is a preferred producer for researchers and  diagnostic companies to supply  this critical tumor marker for multiple myelomas and lymphomas.

Beta 2 MICROGLOBULIN is an important blood plasma protein used for detecting some blood cell cancers as lymphomas and multiple myelomas and for detecting kidney damage. B2M is used for prognosis because it is found on the surface of many cells, including lymphocytes, and in small amounts in the blood and urine. According to the CDC, there are over 10,000 deaths of multiple myeloma per year and over 20,000 people dying from lymphoma just in the United States alone. Lymphoma is the most common form of blood cancer in the developed world.

“ We feel that Lee Biosolutions is on the forefront of Blood Cell Cancer research  by supplying  highly purified  markers such as Beta 2 Microglobulin to the research community and clinical diagnostic market.  A B2M Test measures the level of B2M in the blood  or urine and is one of the tools used  for identifying disease activity and tumor burden.  With continued  improvements in screening, diagnosis and treatment of blood cancers and kidney damage  more individuals are able to manage their disease earlier and live longer .”  said Burton Lee, President of Lee Biosolutions.

About Lee BioSolutions, Inc.
Lee BioSolutions is an international producer and supplier of high purity finished   proteins.  Headquartered in St. Louis and founded in 2002, the healthcare biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes finished and intermediate proteins  used in drug discovery and development , clinical diagnosis and product testing. These include Alpha Feto Protein used in detection of liver cancer and germ cell tumors, Beta 2 Microglobulin used to detect multiple myeloma, chronic lymphocytic leukemia and some lyophomas,  THYROGLOBULIN for detecting Thyroid Cancer,   and Lactate Dehydrogenase used to assess state and prognosis of Germ cell tumors.    The company is ISO 9001:2008 certified, FDA registered and approved by APHIS for exporting . To learn more about Lee BioSolutions visit www.LeeBio.com or call 314-968-1091.
Posted by Burton on January 30th, 2012 in Headlines  ⟩  0 comments
Lee BioSolutions Inc, an international manufacturer, producer and supplier of high purity proteins and antigens announces that it will supply high purity Hemoglobin A1C to the Diabetes Market. Hemoglobin A1C is isolated from Red Blood cells and is used as an indicator of blood glucose in a diabetic patient. The A1C test is an important test in the diagnosis and management of diabetes.

According to the World Health Organization there are over 350 million people who have diabetes worldwide. Current news reports say that 50% of individuals living in the United States are either pre-diabetic or diabetic.

Lee Biosolutions recognizes the growing diabetes market and is committed in providing the highest quality Hemoglobin A1C protein and is working closely with major diagnostic companies to meet demand of this highly desirable indicator. . In addition to isolating A1C from red blood cells, Lee Biosolutions is also providing prediabetic, diabetic Type 1 and diabetic Type 2 urine from donors.

“Lee Biosolutions is on the forefront of Diabetes research by supplying highly purified markers such as Hemoglobin A1C,“ said Burton Lee, President of Lee Biosolutions . “ What is unique about this test is that patients do not need to fast as with the common fasting plasma glucose test. Since HbA1C builds up in red blood cells throughout the lifetime of diabetic patients, its levels represent an excellent record of blood glucose levels over the previous 2-3 months. We are happy to be a part of early diagnosis of a disease that is so common but is taken so much for granted.“

About Lee BioSolutions, Inc.
Lee BioSolutions is an international producer and supplier of high purity finished human proteins. Headquartered in St. Louis and founded in 2002, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee BioSolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include Low Denisity Lipoprotein (LDL),High Denisity Lipoprotein(HDL), Myeloperoxidase, C-Reactive Protein, CkMB and Troponin, The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee BioSolutions visit http://www.LeeBio.com or call 314-968-1091.
Posted by Burton on May 25th, 2011 in Headlines  ⟩  0 comments

St. Louis, MO Lee Biosolutions has announced the introduction of a new Monoclonal Antibody anti-Human Apolipoprotein Apo A1 for cardiovascular research.

APOA-1 is a major protein of plasma High Density Lipoprotein. ApoA1 participates in the reverse transport of cholesterol from tissues to the liver for excretion. APOA1 is a cofactor for LCAT, which is responsible for the formation of most plasma cholesteryl esters.

Lee's monoclonal antibody was purified from Balb/C mice and immunized with highly purified human apoloipoprotein A-1. The mouse spleen and lymph node lymphocytes were fused to firm hybridomas. Lee Biosolutions purified Mouse IgG1 kappa antibody was purified from tissue culture fluid using protein a chromatography. the monoclonal antibody reacts with human apolipoprotein A-1 by elisa and blotting applications.

According to Burton Lee, "Lee Biosolutions is in constant communication with its customers to determine trends and anticipate product needs before they happen. Innovative purification procedures continues to be key to the success of Lee Biosolutions business. We are offering a number of related lipoproteins from ApoA1 to ApoE lipoporteins for research.

"We understand the critical role our products play in the clinical research process", Lee said. By maintaining higher purity and quality standards, we aim to provide clients with a wider variety of reliably consistent products which makes us the preferred producer of kidney proteinS.

Lee Biosolutions Inc is a leader in the development and marketing of high valued specialty products including Lipoproteins used in Cardiovascular and Lupas research.

Working closely with major diagnostic companies and clinical researchers worldwide in autoimmune studies, cardiovascular and cancer research, Lee Biosolutions, Inc delivers over 400 products to more than 40 countries around the globe. To learn more about how LEE BIOSOLUTIONS helps to make research work, visit www.leebio.com

Posted by Burton on May 25th, 2011 in Headlines  ⟩  0 comments

Lee Biosolutions increases production of Myeloperoxidase (MPO)
New research suggest that MPO can help breakdown toxic nanomaterials in humans

May 19, 2010; St. Louis, MO - In the minds of many, iPads and mini notebooks are among the "wonders" of the new age of computing. While this may be quite true, the technology that allows for computer chips to become smaller is made possible by the carbon nanotube - a material also proven to be harmful to workers handling it over long periods of time. The good news is that researchers at the University of Pittsburg have identified that the enzyme myeloperoxidase (MPO) can reduce the harmful effects of carbon nanotubes to exposed individuals. Lee Biosolutions, one of the forerunners in MPO production, is increasing its production of the enzyme to meet the demand these new findings will create.

According to Lee Biosolutions president, Burton Lee, carbon nanotubes are often referred to as a wonder material for many household items aside from electronics and compact computing devices, such as components in cars and anti-wrinkle chemicals in clothing. While not all nanotubes are proven dangerous, some behave much like asbestos in the lungs. The use of carbon nanotubes has significantly increased as electronics and plastics have become more prevalent, and the threat to exposed workers can lead to cancer 30 to 40 years down the road.

MPO is a peroxidase enzyme, most abundantly present in neutrophil granulocytes (a subtype of white blood cells). MPO has a heme pigment, which causes its green color in secretions rich in neutrophils, such as pus and some forms of mucus. In the human body, MPO produces hypochlorous acid (HOCl) from hydrogen peroxide (H2O2) and chloride anion (Cl-) during the neutrophil's respiratory burst, and requires heme as a cofactor. Hypochlorous acid is cytotoxic, so the MPO is used by the neutrophil to kill bacteria and other pathogens.

"Our native human myeloperoxidase (MPO) enzyme is already being used in cardiac and autoimmune assays in research worldwide. Demand for MPO will continue to increase as exposure to and handling of carbon nanotubes increases. We have an opportunity to counteract the many health issues we are just beginning to face, and Lee Biosolutions is prepared with continuous, increased production of MPO." said Lee.

For over 30 years, Lee Biosolutions has been providing proteins, enzymes and other materials to research facilities around the country that work to advance the healthcare industry. By providing Solutions on Demand, Lee Biosolutions has become the preferred source for materials such as myeloperoxidase (MPO). For more information, visit Lee Biosolutions at www.leebio.com.